Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
inhibits cap-dependent endonuclease
|
| gptkbp:age |
not recommended for children under 12 years
|
| gptkbp:approves |
gptkb:2018
gptkb:Japan gptkb:United_States |
| gptkbp:availability |
available in multiple countries
|
| gptkbp:brand |
gptkb:Xofluza
|
| gptkbp:category |
gptkb:C
|
| gptkbp:clinical_trial |
Phase III
single-dose treatment ongoing studies for efficacy in different populations |
| gptkbp:contraindication |
hypersensitivity to the drug
|
| gptkbp:developed_by |
gptkb:Shionogi
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
single dose treatment
|
| gptkbp:excretion |
primarily through feces
|
| https://www.w3.org/2000/01/rdf-schema#label |
baloxavir marboxil
|
| gptkbp:indication |
acute uncomplicated influenza
|
| gptkbp:ingredients |
C19 H22 F2 N2 O4 S
|
| gptkbp:interacts_with |
may interact with certain vaccines
|
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
J05 AX
|
| gptkbp:is_effective_against |
reduces duration of influenza symptoms
|
| gptkbp:is_used_for |
treatment of influenza
|
| gptkbp:lifespan |
approximately 35 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Xofluza
|
| gptkbp:metabolism |
primarily by glucuronidation
|
| gptkbp:pharmacokinetics |
high oral bioavailability
rapidly reduces viral load |
| gptkbp:population |
adults and adolescents
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
recommended for high-risk patients
|
| gptkbp:reproduction |
use with caution
|
| gptkbp:research_focus |
influenza treatment alternatives
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
headache
nausea diarrhea |
| gptkbp:supply_chain |
manufactured by Shionogi
|
| gptkbp:targets |
gptkb:virus
|
| gptkbp:type_of |
198560-15-0
|
| gptkbp:water_resistance |
may develop in some strains of influenza
|
| gptkbp:weight |
396.45 g/mol
|
| gptkbp:bfsParent |
gptkb:virus
|
| gptkbp:bfsLayer |
4
|